What does PHARMA BIEN-ÊTRE do?

PHARMA BIEN-ÊTRE is a pharmacy in Namur. Public Limited, started on 28 October 2021, 1 establishment.

What is the address of PHARMA BIEN-ÊTRE?

The registered office of PHARMA BIEN-ÊTRE is located at Rue de Sedent(JB) 205 box 21, 5100 Namur.

Is PHARMA BIEN-ÊTRE still active?

Yes. According to the CBE (29 October 2026) PHARMA BIEN-ÊTRE is active, legal situation “Normale toestand”, started on 28 October 2021.

Is PHARMA BIEN-ÊTRE registered on Peppol?

Yes, PHARMA BIEN-ÊTRE is registered on the Peppol network with ID 0208:0776600905.

What is the enterprise number of PHARMA BIEN-ÊTRE?

The enterprise number of PHARMA BIEN-ÊTRE is BE0776600905.

When was PHARMA BIEN-ÊTRE founded?

PHARMA BIEN-ÊTRE was founded on 28 October 2021.

Who are the directors of PHARMA BIEN-ÊTRE?

According to the 2025 annual accounts, the directors of PHARMA BIEN-ÊTRE are: Mikael Tilman.

Is PHARMA BIEN-ÊTRE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 28 October 2021; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did PHARMA BIEN-ÊTRE make in 2025?

PHARMA BIEN-ÊTRE posted a profit after taxes of € 397,140 in financial year 2025.

What is the revenue of PHARMA BIEN-ÊTRE?

As a small company, PHARMA BIEN-ÊTRE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 565,872.

How much does an employee at PHARMA BIEN-ÊTRE earn?

The average wage cost per full-time employee at PHARMA BIEN-ÊTRE was € 97,900 in 2025: staff costs of € 303,530 for 3.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMA BIEN-ÊTRE have?

According to the 2025 annual accounts, PHARMA BIEN-ÊTRE has 3.1 full-time equivalents (FTE).

PHARMA BIEN-ÊTRE (Public Limited) - Namur - BE0776600905

Dossier PHARMA BIEN-ÊTRE, printed on 29 October 2026 from databakkes.be/en/0776600905/pharma-bien-etre. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMA BIEN-ÊTRE from Namur, company number BE0776600905, closed financial year 2025 with a result of € 397,140 after tax. For that financial year PHARMA BIEN-ÊTRE recorded a gross margin of € 565,872 and equity of € 1.2 million. Compared with financial year 2024, the result moved from € 241,232 to € 397,140. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.

What it is worth Growing

€ 1.2 million

▲ 52% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 397,140

▲ 65% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 194,034

▲ € 148,780 vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 967,257.

People and assets in 2025

Full-time equivalents

3.1

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 303,530

€ 97,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 3,269

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 13 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 3 million

▼ 1% vs 2024

€ 229,813 is repaid this year. At this pace the long-term loan is gone in ≈ 13 years.

Owed to suppliers

€ 109

▼ 98% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 60,065

▼ 38% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 209,813 Gross margin 2022: € 209,813 First fiscal year in the series	€ 205,378 Gross margin 2023: € 205,378 ▼ 2% vs 2022 (€ 209,813) Unfavourable step	€ 217,944 Gross margin 2024: € 217,944 ▲ 6% vs 2023 (€ 205,378) Favourable step	€ 565,872 Gross margin 2025: € 565,872 ▲ 160% vs 2024 (€ 217,944) Favourable step	▲ 160%
Profit after taxes	€ 132,745 Profit after taxes 2022: € 132,745 First fiscal year in the series	€ 196,139 Profit after taxes 2023: € 196,139 ▲ 48% vs 2022 (€ 132,745) Favourable step	€ 241,232 Profit after taxes 2024: € 241,232 ▲ 23% vs 2023 (€ 196,139) Favourable step	€ 397,140 Profit after taxes 2025: € 397,140 ▲ 65% vs 2024 (€ 241,232) Favourable step	▲ 65%
Equity	€ 332,745 Equity 2022: € 332,745 First fiscal year in the series	€ 528,884 Equity 2023: € 528,884 ▲ 59% vs 2022 (€ 332,745) Favourable step	€ 770,117 Equity 2024: € 770,117 ▲ 46% vs 2023 (€ 528,884) Favourable step	€ 1,167,257 Equity 2025: € 1,167,257 ▲ 52% vs 2024 (€ 770,117) Favourable step	▲ 52%
Total debts	€ 2,998,724 Total debts 2022: € 2,998,724 First fiscal year in the series	€ 2,887,357 Total debts 2023: € 2,887,357 ▼ 4% vs 2022 (€ 2,998,724) Favourable step	€ 3,444,231 Total debts 2024: € 3,444,231 ▲ 19% vs 2023 (€ 2,887,357) Unfavourable step	€ 3,709,967 Total debts 2025: € 3,709,967 ▲ 8% vs 2024 (€ 3,444,231) Unfavourable step	▲ 8%
Cash	€ 78,469 Cash 2022: € 78,469 First fiscal year in the series	€ 68,565 Cash 2023: € 68,565 ▼ 13% vs 2022 (€ 78,469) Unfavourable step	€ 45,253 Cash 2024: € 45,253 ▼ 34% vs 2023 (€ 68,565) Unfavourable step	€ 194,034 Cash 2025: € 194,034 ▲ € 148,780 vs 2024 (€ 45,253) Favourable step	▲ € 148,780
Land & buildings	-	-	€ 423,396 Land & buildings 2024: € 423,396 First fiscal year in the series	€ 599,867 Land & buildings 2025: € 599,867 ▲ 42% vs 2024 (€ 423,396) Unchanged	▲ 42%
Retained profit	€ 132,745 Retained profit 2022: € 132,745 First fiscal year in the series	€ 328,884 Retained profit 2023: € 328,884 ▲ 148% vs 2022 (€ 132,745) Favourable step	€ 570,117 Retained profit 2024: € 570,117 ▲ 73% vs 2023 (€ 328,884) Favourable step	€ 967,257 Retained profit 2025: € 967,257 ▲ 70% vs 2024 (€ 570,117) Favourable step	▲ 70%
Bank debt	€ 2,692,546 Bank debt 2022: € 2,692,546 First fiscal year in the series	€ 2,522,744 Bank debt 2023: € 2,522,744 ▼ 6% vs 2022 (€ 2,692,546) Favourable step	€ 3,059,151 Bank debt 2024: € 3,059,151 ▲ 21% vs 2023 (€ 2,522,744) Unfavourable step	€ 3,019,450 Bank debt 2025: € 3,019,450 ▼ 1% vs 2024 (€ 3,059,151) Favourable step	▼ 1%
Balance sheet total	€ 3,331,469 Balance sheet total 2022: € 3,331,469 First fiscal year in the series	€ 3,416,241 Balance sheet total 2023: € 3,416,241 ▲ 3% vs 2022 (€ 3,331,469) Unchanged	€ 4,214,348 Balance sheet total 2024: € 4,214,348 ▲ 23% vs 2023 (€ 3,416,241) Unchanged	€ 4,877,224 Balance sheet total 2025: € 4,877,224 ▲ 16% vs 2024 (€ 4,214,348) Unchanged	▲ 16%
Employees (FTE)	-	-	-	3.1 Employees (FTE) 2025: 3.1 First fiscal year in the series

Key figures of PHARMA BIEN-ÊTRE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMA BIEN-ÊTRE?

What happened at PHARMA BIEN-ÊTRE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 30, 2026 New annual accounts for financial year 2025: profit of € 397,140 (▲ 65% vs 2024). Source: NBB ↗
Oct 28, 2021 New establishment in Namur. KBO
Oct 28, 2021 Start of the company according to the CBE. KBO

In short

From € 132,745 profit in 2022 to € 397,140 profit in 2025.

Paid € 151,898 in corporate taxes since 2022.

Best year ever: 2025, with € 397,140 profit.

On average € 182,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Mikael Tilman

PHARMA BIEN-ÊTRE

Pharmacie Tilman 100%

Pharmacie Huart 100%

Tilman Han 100%

Pharmacie Tilman Assesse 100%

Behind PHARMA BIEN-ÊTRE is Mikael Tilman. It owns 100% of Pharmacie Tilman, 100% of Pharmacie Huart, 100% of Tilman Han and 100% of Pharmacie Tilman Assesse itself.

Directors

According to the 2025 annual accounts

Mikael Tilman

Director

Also active at: PHARMACIE TILMAN, Pharmacie Tilman Han, Pharmacie Tilman Assesse

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de Sedent(JB) 205 box 21

5100 Namur

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

LES ATELIERS DU MIEUX VIVRE

Association des Copropriétaires (Bloc C) Résidence Les Dentelles à Jambes, rue de Sedent, 205

FONTANOVA

€ 32,847 gross margin · 2025

Groupe Tilman

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0776.600.905

VAT number

BE 0776.600.905

Registered office

Rue de Sedent(JB) 205 bus 21, 5100 Namur

Names & denominations

PHARMA BIEN-ÊTRE

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

28 October 2021

Peppol

Active · Active since 17 Jul 2026

Activities · NACE

Detailhandel in farmaceutische producten

Activiteiten van holdings

Holdings

Lease van intellectuele eigendom en vergelijkbare producten, met uitzondering van werken onder auteursrecht

Verhuur en exploitatie van eigen of geleased niet-residentieel onroerend goed, exclusief terreinen

Verhuur en exploitatie van terreinen

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMA BIEN-ÊTRE

Financials

What happened to PHARMA BIEN-ÊTRE?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions